Guinea vs South Sudan: Average cost of multi drug-resistant tuberculosis treatment
Guinea
616 constant 2022 US$
in 2024
South Sudan
682 constant 2022 US$
in 2024
Guinea rank
71st
South Sudan rank
69th
Average cost of multi drug-resistant tuberculosis treatment over time
- Guinea
- South Sudan
How they compare
South Sudan currently reports 682 constant 2022 US$ against 616 constant 2022 US$ in Guinea, a difference of 66 constant 2022 US$.
That makes South Sudan's figure about 1.1 times Guinea's.
The two have swapped places 2 times across 6 shared years of data; in 2019 it was South Sudan ahead.
Guinea ranks 71st and South Sudan ranks 69th of 92 countries.
South Sudan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guinea | South Sudan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 306 constant 2022 US$ | 1,678 constant 2022 US$ | 1,372 constant 2022 US$ | South Sudan |
| 2020s | 1,127 constant 2022 US$ | 2,265 constant 2022 US$ | 1,138 constant 2022 US$ | South Sudan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Guinea or South Sudan?
- South Sudan, at 682 constant 2022 US$ against 616 constant 2022 US$ in Guinea as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Guinea and South Sudan?
- 66 constant 2022 US$, with South Sudan ahead.
- How many years of comparable data are there for Guinea and South Sudan?
- 6 years are reported by both, from 2019 to 2024.
- How do Guinea and South Sudan rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Guinea ranks 71st and South Sudan ranks 69th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.